Bayer is facing more bad news for its contraceptive implant Essure, as a new study shows that women outfitted with the company's device are more likely to need follow-up surgeries compared to individuals who undergo a traditional sterilization procedure.
How do you keep a 22-year-old injectable multiple sclerosis therapy competitive in the face of threats from high-flying oral contenders? Bayer has an idea. The company recently won FDA approval for Betaconnect, an automatic injector it thinks can help keep its standby treatment, Betaseron, in the game.
Bayer is hoping that a new electronic autoinjector will slow the fall of lucrative multiple sclerosis drug Betaseron off of the dreaded patent expiry sales cliff.
Bayer has set up a system to manage its omics data analysis workflow. The system is the result of Bayer's collaboration with Genedata, which has provided its data management and analysis software to a platform that also draws on the capabilities of the open-source iRODS.
Bayer has faced a rocky road with its contraceptive implant Essure, with the FDA launching an investigation earlier this year following claims of harmful--and in some cases, lethal--side effects and false trial data for the product. Now the company is facing more pushback after an FDA panel came down on the company for not collecting key safety data for its device.
Bayer is facing disheartening news for its controversial birth control device Essure prior to an FDA panel meeting to discuss the product's safety, as new analysis by the agency shows a spike in reports from women who had bad reactions to the device.
Change is coming for Bayer--and with it, change at the top. The German pharma has outlined its plans for retooling, post-plastics division divestment--and they involve three operational arms, each headed up by a company vet.
Bayer's plastics unit spinoff is in the works for Q4, sources tell Reuters. At that time, the German company plans to carry out an IPO for the business, to be dubbed Covestro, and it's aiming to raise about E2.5 billion ($2.8 billion).
Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.
Bayer is pushing forward with a new heart-failure treatment that could eventually contend with Novartis' blockbuster-in-waiting Entresto, mapping out a wide Phase III program for its oral drug.